The OmniSeq Advance Assay uses two different testing methodologies: IHC and DNA-sequencing, RNA-sequencing and MSI performed by NGS.
88360-TC, 88360-26, 81301, 88342, 81455, 88381
Different cancer types
Non-Small-Cell Lung Cancer (NSCLC)
FFPE tissue block preferred. Unstained slides accepted.
Block is preferred, or send 20 unbaked, positively charged, unstained slides cut at 5 μm.
Primary tumor type and stage of disease required and needs to be included in the test requisition. Please include the pathology report when submitting a sample. If a pathology report is not received with the sample, testing will be delayed.
Causes for Rejection
Tumor block containing insufficient tumor; broken or stained slides; decalicified bone biopsies; cytology smears. Specimens with very small amounts of tumor and/or less than requested number of slides will be accepted with the caveat that complete testing may not be possible.
FFPE blocks are stored at room temperature and shipped with no special precautions, except when daily outside temperatures exceed 35°C, and then ship with cool packs to avoid paraffin meltdown.
OmniSeq AdvanceSM includes PD-L1( FDA-approved), CD8 by IHC, microsatellite instability (MSI), tumor mutational burden (TMB) , RNA-sequencing of over 50 critical immune markers to characterize the tumor micro-environment (TME), and somatic genomic profiling of 144 genes.
Only OmniSeq Advance synthesizes the most relevant biomarkers for selecting targeted therapies and provides a comprehensive immune profile to characterize DNA damage (TMB and MSI), TILs, T-cell receptor signaling, and other markers of immune stimulation and escape. A single test with actionability that reaches 99% by combining indicated and contraindicated biomarker results for targeted therapy and immunotherapy.1
1. Based on OmniSeq Internal data